Cargando…

Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells

Detalles Bibliográficos
Autores principales:	Karschnia, Philipp, Strübing, Felix, Teske, Nico, Blumenberg, Viktoria, Bücklein, Veit L., Schmidt, Christian, Schöberl, Florian, Dimitriadis, Konstantinos, Forbrig, Robert, Stemmler, Hans-Joachim, Tonn, Joerg-Christian, von Bergwelt-Baildon, Michael, Subklewe, Marion, von Baumgarten, Louisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886479/ https://www.ncbi.nlm.nih.gov/pubmed/33615147 http://dx.doi.org/10.1097/HS9.0000000000000533

Ejemplares similares

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report
por: Rejeski, Kai, et al.
Publicado: (2021)

Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment
por: Schoeberl, Florian, et al.
Publicado: (2022)

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells
por: Karschnia, Philipp, et al.
Publicado: (2022)

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
por: Karschnia, Philipp, et al.
Publicado: (2021)

Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity
por: Stoecklein, Sophia, et al.
Publicado: (2023)

Advanced imaging findings in stroke-like migraine attacks after radiation therapy (SMART) syndrome
por: Teske, Nico, et al.
Publicado: (2022)

Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
por: Rejeski, Kai, et al.
Publicado: (2023)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION OF AN IDENTICAL PRODUCT: HOST ENVIRONMENT AND DISEASE CHARACTERISTICS DETERMINE THE OUTCOME OF TREATMENT
por: Frölich, L., et al.
Publicado: (2022)

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
por: Rejeski, Kai, et al.
Publicado: (2022)

Ten things the hematologist wants you to know about CAR-T cells
por: Böll, Boris, et al.
Publicado: (2020)

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
por: Rejeski, Kai, et al.
Publicado: (2023)

Frequency and Prognostic Relevance of Volumetric MRI Changes in Contrast- and Non-Contrast-Enhancing Tumor Compartments between Surgery and Radiotherapy of IDHwt Glioblastoma
por: Teske, Nico, et al.
Publicado: (2023)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
por: Rejeski, Kai, et al.
Publicado: (2023)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
por: Rohrbacher, Lisa, et al.
Publicado: (2021)

Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment
por: Winkelmann, Michael, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival
por: Winkelmann, Michael, et al.
Publicado: (2022)

Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria
por: Winkelmann, Michael, et al.
Publicado: (2023)

Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
por: Winkelmann, Michael, et al.
Publicado: (2023)

Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
por: Skalt, Daniela, et al.
Publicado: (2022)

P1445: MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR CARS AND BITES INCREASES GUIDELINE ACCESSIBILITY AND REDUCES TIME TO APPLY EVIDENCE-BASED PATIENT CARE
por: Blumenberg, V., et al.
Publicado: (2022)

Subventricular zone involvement is associated with worse outcome in glioma WHO grade 2 depending on molecular markers
por: Karschnia, Philipp, et al.
Publicado: (2021)

Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies
por: Cordas dos Santos, David M., et al.
Publicado: (2022)

Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II
por: Karschnia, Philipp, et al.
Publicado: (2020)

Shunt dependency in supratentorial intraventricular tumors depends on the extent of tumor resection
por: Teske, Nico, et al.
Publicado: (2023)

In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer
por: Xu, Tao, et al.
Publicado: (2023)

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
por: Blumenberg, Viktoria, et al.
Publicado: (2023)

In vivo two-photon characterization of tumor-associated macrophages and microglia (TAM/M) and CX3CR1 during different steps of brain metastasis formation from lung cancer
por: Zhang, Wenlong, et al.
Publicado: (2021)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
por: Bücklein, Veit, et al.
Publicado: (2023)

Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice
por: Mulazzani, Matthias, et al.
Publicado: (2019)

Teaching an old dog new tricks: next-generation CAR T cells
por: Tokarew, Nicholas, et al.
Publicado: (2018)

Cytokine release syndrome
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2018)

Der knochenmarktransplantierte Patient auf der Intensivstation
por: Stecher, S.-S., et al.
Publicado: (2021)

SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine
por: Karschnia, Philipp, et al.
Publicado: (2021)

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE
por: Bücklein, V., et al.
Publicado: (2022)

The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine
por: Katzendobler, Sophie, et al.
Publicado: (2022)

Postoperative [(68)Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1
por: Teske, Nico, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_po0mj5c8v9ve12865b81h9i1te